September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Development and analysis of a new rat glaucoma model
Author Affiliations & Notes
  • Ayumi Nakagawa
    Research & Development Division, Senju Pharmaceutical Co., Ltd., Kobe, Japan
  • Osamu Sakai
    Research & Development Division, Senju Pharmaceutical Co., Ltd., Kobe, Japan
  • Hideki Tokushige
    Research & Development Division, Senju Pharmaceutical Co., Ltd., Kobe, Japan
  • Takashi Fujishiro
    Saitama Red Cross Hospital, Saitama, Japan
  • Makoto Aihara
    Department of Ophthalmology, University of Tokyo, Tokyo, Japan
  • Footnotes
    Commercial Relationships   Ayumi Nakagawa, Senju Pharmaceutical Co., Ltd. (E); Osamu Sakai, Senju Pharmaceutical Co., Ltd. (E); Hideki Tokushige, Senju Pharmaceutical Co., Ltd. (E); Takashi Fujishiro, None; Makoto Aihara, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 2523. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Ayumi Nakagawa, Osamu Sakai, Hideki Tokushige, Takashi Fujishiro, Makoto Aihara; Development and analysis of a new rat glaucoma model. Invest. Ophthalmol. Vis. Sci. 2016;57(12):2523.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Glaucoma is mainly caused by glaucomatous optic neuropathy (GON) characterized by structural and functional damages, resulting in progressive loss of retinal ganglion cells (RGCs). Several animal glaucoma models based on increasing intraocular pressure (IOP) have been developed, however, it is difficult to obtain the consistent animal model with long-lasting IOP elevation. In addition, these models cannot be completely extrapolated to the properties of the complex pathogenesis of GON. In this study, we tried to establish a novel rat glaucoma model which achieved long-lasting IOP elevation with glaucomatous damage.

Methods : Conjunctival fibroblasts isolated from Sprague-Dawley rat eyes were cultured and injected into rat anterior chamber. IOP was measured using TonoLab® for 28 days. The changes of anterior and posterior segments were analyzed histologically. The numbers of RGCs labeled with brn3a in the flat-mounted retina were measured using image visualization software. The rate of RGC death was defined as the percentage of the decreased number of cells in the cell injected eye against the contralateral control eye of same animal. All these histological analyses were performed at 28 days after cell injection.

Results : The IOP started to elevate 3 or 7 days after cell injection and it sustained higher than that of the contralateral control eyes until 28 days. The mean IOP after 28 days was 31.4±10.5 mmHg in cell injected eyes (n=6), while that of control eyes was 13.6±2.6 mmHg (n=6). The size of eyes gradually expanded and cell accumulation was observed in anterior chamber. Histological analysis of anterior sections showed that the angle of the cell injected eyes was completely occluded. Enlargement of optic nerve head cupping was also observed in the cell injected eyes. Cell injection induced activation of Müller glial cells as indicated by increased glial fibrillary acidic protein (GFAP) expression. The rate of RGC death in cell injected eyes was 61.4%±33.7% (n=6, P<0.05, paired one-sided t-test compared with control group).

Conclusions : We developed a valuably rat chronic ocular hypertension model induced by conjunctival fibroblasts injection. This model showed glaucomatous pathology such as enlargement of optic nerve head cupping and RGC loss. It would provide valuable information about the pathogenic mechanism of glaucoma and be also useful for evaluation of neuroprotective drugs.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×